Genetic variability of HIF1A and response to treatment with cisplatin in combination with pemetrexed or gemcitabine in patients with malignant mesothelioma

Treatment of malignant mesothelioma (MM) still relies on chemotherapy with cisplatin in combination with pemetrexed or other drugs. Studies indicate that hypoxic conditions within tumour tissue may reduce responsiveness to cisplatin-based chemotherapy. Hypoxia-inducible factors (HIF) play an important role in regulation of cellular adaptation to hypoxia. The aim of our study was to investigate single nucleotide polymorphisms (SNPs) in the HIF1A gene coding for the regulatory alpha subunit (HIF-1A) and their role in the response to chemotherapy in patients with MM.

Patients and methods

Our retrospective genetic association study included 234 patients with MM, who were treated with a combination of cisplatin/pemetrexed or cisplatin/gemcitabine at the Institute of Oncology Ljubljana between January 2001 and September 2018. Selected HIF1A SNPs (rs1154965, rs11549467, and rs2057482) were genotyped using the competitive allele-specific polymerase chain reaction (KASP). Additionally, we used a TaqMan assay for independent confirmation of rs11549465 genotyping results. The impact of the SNPs on response to chemotherapy was analysed using logistic regression. For survival analysis, we used the Kaplan-Meier method and Cox regression.

Results

In heterozygotes with the HIF1A rs11549465 CT genotype, response to chemotherapy was significantly worse compared to homozygotes with the CC genotype, but only after adjustment for weight loss and CRP (RO_adj = 0.37; 95% CI = 0.14–0.97; P_adj = 0.044). HIF1A rs11549467 and rs2057482 were not associated with response to chemotherapy (all P > 0.05). None of the investigated SNPs were associated with progression-free survival or overall survival (all P > 0.05).

Conclusions

Among the investigated HIF1A SNPs, only rs11549465 has showed association with a worse response to chemotherapy after the adjustment for clinical parameters. The findings of this study have improved our understanding of the role of HIF1A polymorphisms in MM and may offer valuable insights into their impact on other cancers as well.

Langue:: Anglais

Périodicité:: 4 fois par an
Sujets de la revue:: Médecine, Médecine clinique, Médecine interne, Hématologie, oncologie, Radiologie

RSS Feed de la revue

Genetic variability of HIF1A and response to treatment with cisplatin in combination with pemetrexed or gemcitabine in patients with malignant mesothelioma

Matic Setina

Eva Setina

Ziga Doljak

Katja Goricar

Vita Dolzan

Viljem Kovac

Publié en ligne: 05 sept. 2025

Pages: 403 - 411

Reçu: 15 juin 2025

Accepté: 19 juil. 2025

DOI: https://doi.org/10.2478/raon-2025-0049

Mots clésmalignant mesothelioma, chemotherapy, hypoxia-inducible factor, polymorphism

© 2025 Matic Setina et al., published by Sciendo

This work is licensed under the Creative Commons Attribution 4.0 International License.

Background

Patients and methods

Results

Conclusions

Mots clés
malignant mesothelioma, chemotherapy, hypoxia-inducible factor, polymorphism